Back to results
US 2023/0000956 A1Published application
Combination therapy with glucarpidase with methotrexate/rituximab to treat cns lymphoma
OwnerLauren SCHAFF, Christian GROMMES +2inventors
InventorsLauren SCHAFF, Christian GROMMES, Lisa DEANGELIS, Burt NABORS
Life of this patent
Estimating the term…
Abstract
The present technology relates to methods comprising the administration of methotrexate and glucarpidase to treat central nervous system lymphoma in a subject in need thereof. Kits for use in practicing the methods are also provided.
Claims28
A method for treating central nervous system lymphoma in a subject in need thereof comprising
- (a) administering to the subject an effective amount of methotrexate;
- and
- (b) administering to the subject an amount of glucarpidase that is sufficient to reduce the level of methotrexate in the subject's serum by >90%, wherein the glucarpidase is administered 10 to 48 hours following administration of methotrexate, and
- wherein steps (a)-(b) are performed for 1, 2, 3, 4, 5, 6, 7, 8 or more cycles.
1 more element
A method for reducing the toxicity associated with high dose methotrexate therapy in a subject in need thereof comprising
- (a) administering to the subject an effective amount of methotrexate;
- and
- (b) administering to the subject an amount of glucarpidase that is sufficient to reduce the level of methotrexate in the subject's serum by >90%, wherein the glucarpidase is administered 10 to 48 hours following administration of methotrexate,
- wherein steps (a)-(b) are performed for 1, 2, 3, 4, 5, 6, 7, 8 or more cycles, and wherein the subject suffers from or is diagnosed with central nervous system lymphoma.
1 more element
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.